Int Ophthalmol (2018) 38:943–949 https://doi.org/10.1007/s10792-017-0538-y ORIGINAL PAPER Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study . . M. A. Khan Varakutti Mallika Dattakiran Joshi Received: 6 October 2016 / Accepted: 17 April 2017 / Published online: 21 April 2017 Springer Science+Business Media Dordrecht 2017 Abstract Results The mean visual gain in the two groups early Purpose To compare visual and anatomical recovery and delayed intervention was 0.38 log MARs and 0.15 of immediate versus deferred intravitreal Beva- log MAR units, respectively, and the superior vision cizumab for the treatment of macular oedema sec- gain in the early intervention group was statistically ondary to branch retinal vein occlusion (BRVO). signiﬁcant (p \ 0.001). The difference in visual Methods In a pilot study, 40 treatment naı¨ve patients improvement between the two groups persisted till of branch retinal vein occlusion with macular oedema 1 year of follow-up. The early intervention group and vision 6/12 or less presenting within one month of required fewer injections (2.6 ± 71 vs. 3.5 ± 0.51), onset were randomised into 2 groups (20 each) to and rescue laser treatment (15 vs. 25%) as compared to receive
International Ophthalmology – Springer Journals
Published: Apr 21, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera